-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

499 Selective Support of CAR-T Cell Therapies By Cis-Targeted IL-2 Enhances Anti-Tumor Activity and Obviates the Need for Lymphodepletion in Non-Human Primates

Program: Oral and Poster Abstracts
Type: Oral
Session: 702. CAR-T Cell Therapies: Basic and Translational: Enhancements in CAR-T Cell Signaling, Delivery & Manufacturing
Hematology Disease Topics & Pathways:
Research, Lymphoid Leukemias, Combination therapy, Translational Research, Lymphomas, Diseases, Treatment Considerations, Lymphoid Malignancies
Sunday, December 8, 2024: 9:30 AM

Sara Sleiman1*, Tyler Hansen, MS1*, Nathan D Mathewson, PhD2, Feng Shen, MD, PhD1*, Miroslaw Kozlowski, PhD1*, Olga Shestova, PhD1*, Maksim Shestov1*, Danuta Jarocha, PhD1*, Vanessa Gonzalez1*, Joseph A. Fraietta, PhD1*, Hannah Thomas3*, Jack Swain3*, Raimon Duran-Struuck, PhD, DVM3*, Kelly D. Moynihan, PhD2*, Paul Bessette2*, Chris Kimberlin2*, Meghana Sukthankar2*, Terrence Park2*, Andy Yeung, PhD2*, Ivana Djuretic, PhD2* and Saar Gill, MD, PhD1,4

1Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
2Asher Biotherapeutics, South San Francisco, CA
3Department of Pathobiology, University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA
4University of Pennsylvania, Philadelphia, PA

Limited in vivo persistence and the need for lymphodepleting chemotherapy are ongoing challenges in CAR T cell therapy for hematologic malignancies. In vivo behavior of CAR T cells has shown a strong correlation with improved outcomes, leading to an interest in developing approaches to enhance the expansion and persistence of infused CAR T cells. Exogenous cytokines such as IL-2 can be administered in vivo, but are associated with adverse effects and have the potential to stimulate regulatory T cells, thus impeding the immune response. Lymphodepletion aids CAR T cell function but causes pancytopenia and associated complications. To address these challenges, we developed a CAR T-specific IL-2 fusion molecule that selectively activates CAR T cells by recognizing an extracellular tag. We hypothesized that this method should improve the anti-tumor efficacy and may eliminate the need for lymphodepleting chemotherapy.

We developed an IL-2 molecule that signals selectively on CD19 or CD20-specific CAR T cells by fusing a CAR T cell-targeting antibody to an attenuated IL-2 mutein with diminished binding to IL-2R⍺ and IL-2Rβ. CAR T cell targeting antibodies were against the non-signaling truncated EGFR tag co-expressed with the CAR. While wild-type IL-2 signals on cells expressing its receptor, cis-targeted IL-2 fusion molecules targeting the EGFRt (EGFRt-IL2) enable selective IL-2 signaling by binding in cis to EGFRt on CAR T cells.

Using STAT5 phosphorylation as a readout, in vitro stimulation of human or rhesus macaque CAR T cells that express EGFRt with EGFRt-IL2 led to a >100-fold increase in selectivity compared with wild-type (WT) IL-2. In vivo activity was demonstrated in NSG mice bearing an acute lymphoblastic leukemia (ALL) cell line treated with a “stress” dose of healthy donor anti-CD19-EGFRt CAR T cells with or without EGFRt-IL2. This was subsequently confirmed in a model where the anti-CD19-EGFRt CAR T cells were generated from a lymphoma patient. Response to treatment was accompanied by CAR T cell expansion, resulting in superior survival in the EGFRt-IL2-treated mice with a median overall survival of 61 days compared to 20 days for mice treated with PBS (p = 0.0015).

To test whether IL-2 mutein administration could abrogate the need for lymphodepleting chemotherapy (LD), we treated two rhesus macaques (RM) with a single dose of autologous anti-CD20-EGFRt CAR T cells with (RM#1) or without (RM#2) IL-2 mutein. In the absence of LD, there was no evidence of B cell depletion after CAR T 20 infusion in RM#2, and anti-CAR antibodies were detected from day 11 onwards. In contrast, RM#1 experienced profound B cell depletion in blood and bone marrow lasting approximately 35 days. The animal also experienced cytokine release syndrome (CRS) on day 7 and required dexamethasone and tocilizumab, showing clinical improvement within 12-24 hours. B cell recovery was accompanied by the development of anti-CAR antibodies (which were first detected on day 28). To test whether re-dosing with IL2 mutein at a later time point (day 49) could expand the previously administered CAR T cells and induce B cell aplasia again, we injected RM#1 with the same dose of EGFRt-IL2 on day 49 without re-administering CAR T cells. This time there was no reduction in B cells, and anti-drug antibody (ADA) became detectable on day 62 (14 days post re-dosing).

In summary, EGFRt-IL2 enhances in vivo anti-tumor activity and survival in xenografted mice, enhances the activity of lymphoma patient CAR T cells, and may abrogate the need for lymphodepletion prior to CAR T cell infusion. Temporal control of cis-targeted cytokines directed by anti-tag antibodies represents a promising approach to enhance CAR T cell therapies.

Disclosures: Sleiman: Asher Biotherapeutics: Research Funding. Hansen: Asher Biotherapeutics: Research Funding. Mathewson: Asher Biotherapeutics: Ended employment in the past 24 months. Fraietta: Tceleron Therapeutics, Inc: Membership on an entity's Board of Directors or advisory committees; OverT Bio, Inc: Membership on an entity's Board of Directors or advisory committees; CellFe Biotech: Membership on an entity's Board of Directors or advisory committees; Shennon Biotechnologies Inc.: Membership on an entity's Board of Directors or advisory committees; Cartography Bio: Membership on an entity's Board of Directors or advisory committees; Retro Biosciences: Consultancy; Tmunity Therapeutics: Research Funding; Danaher Corporation: Research Funding. Moynihan: Asher Biotherapeutics: Current Employment. Bessette: Asher Biotherapeutics: Current Employment. Kimberlin: Asher Biotherapeutics: Current Employment. Sukthankar: Asher Biotherapeutics: Current Employment. Park: Asher Biotherapeutics: Current Employment. Yeung: Asher Biotherapeutics: Current Employment. Djuretic: Asher Biotherapeutics: Current Employment. Gill: Asher Biotherapeutics: Research Funding; Novartis: Patents & Royalties, Research Funding; Carisma: Current holder of stock options in a privately-held company; Interius: Current holder of stock options in a privately-held company, Research Funding; Mission Bio: Membership on an entity's Board of Directors or advisory committees.

Previous Abstract | Next Abstract >>
*signifies non-member of ASH